Ajooni Biotech Limited — Important, 28-01-2025: Updates

Ajooni Biotech Limited has issued a corrigendum regarding its Extra Ordinary General Meeting scheduled for January 3, 2025. This corrigendum addresses typographical errors in the explanatory statement for Item No. 3 related to the preferential allotment of 5,00,00,000 convertible warrants. The funds from this issue are intended for working capital, capital expenditures, financing business opportunities, and general corporate purposes, with no specific project designated for the proceeds. The required disclosures regarding project costs and financing are deemed unnecessary given that the issue size is less than Rs. 100 crore. All other aspects of the original notice remain unchanged. Stakeholders should ensure they refer to this corrigendum and stay updated on the company's strategic fund allocation.